of Abasaglar Therapy
recommended initial dose of Abasaglar differs between patients with
T1DM or T2DM (Table 1).1
1. Initiation of Abasaglar Therapy in Patients With T1DM or
treating patients with...
the recommended initial dose of Abasaglar is...
1/3 of the total daily insulin requirement.
units/kg or up to 10 units once daily.
Abasaglar = Abasaglar® (insulin glargine) 100 units/mL; T1DM =
type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.
patients with T1DM, short- or rapid-acting, premeal insulin should be
used to satisfy the remainder of the daily insulin requirements.1
patients with T2DM, the amount and timing of short- or rapid-acting
insulins and dosages of any antihyperglycemic medications may need to
of Abasaglar During a Phase 3 Clinical Study - ELEMENT-2
ELEMENT-2 study, a randomized, double-blind, phase 3 study, compared
the efficacy and safety of Abasaglar vs Lantus in patients with
initial dose of Abasaglar and Lantus for insulin-naïve patients
was 10 units once daily.2
previously prescribed Lantus initiated Abasaglar or Lantus at the
prestudy Lantus dose.2
described by Gerstein et al,3
patients followed a patient-driven titration schedule to increase
their initial insulin dose by 1 unit daily until an FPG concentration
of less than or equal to 5.6 mmol/L (100 mg/dL) was achieved.2
Korea and Taiwan, due to the availability of syringes only marked in
2-unit increments, patients followed a patient-driven titration
schedule to increase their initial dose by 2 units every other day
until an FBG concentration of less than or equal to 5.6 mmol/L (100
mg/dL) was achieved.4
insulin dose increases were permitted if deemed necessary by the
investigator, and insulin dose decreases were permitted if patients
50% of patients in each treatment group injected their basal insulin
in the daytime and approximately 50% of patients injected their dose
in the evening or at bedtime.4
of Insulin Glargine
the Canadian INSIGHT, Implementing New Strategies with Insulin
Glargine for Hyperglycemia Treatment, study with 405 insulin-naïve
patients, introduction of insulin glargine and self-titration of the
glargine dose by a simple protocol of 1 unit per day was 1.7 times
more likely to safely achieve near-physiological control, defined as
2 consecutive HbA1c levels less than 6.5%, than conventional therapy
Abasaglar [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and
safety of LY2963016 insulin glargine and insulin glargine (Lantus®)
in patients with type 2 diabetes who were insulin-naïve or
previously treated with insulin glargine: a randomized, double-blind
controlled trial (the ELEMENT 2 study). Diabetes Obes Metab.
Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding
insulin glargine vs. avoidance of insulin in people with type 2
diabetes on either no oral glucose-lowering agents or submaximal
doses of metformin and/or sulphonylureas. The Canadian INSIGHT
(Implementing New Strategies with Insulin Glargine for Hyperglycaemia
Treatment) study. Diabet Med. 2006;23(7):736-742.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
= Abasaglar® (insulin glargine) 100 units/mL
= a prospEctive, randomized, doubLE-blind coMparison of a long-acting
basal insulin analog LY2963016 to Lantus® in adult patiENTs with
type 2 diabetes mellitus
= fasting blood glucose
= fasting plasma glucose
= glycated hemoglobin
= Lantus® (insulin glargine) 100 units/mL
= oral antihyperglycemic medication
= type 1 diabetes mellitus
= type 2 diabetes mellitus